SCHEDULE: SilverArc Capital Management Discloses Stake in KalVista Pharma

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 5.6% of KalVista Pharmaceuticals Inc.'s Class A Common Stock as of March 31, 2026.

Summary

• SilverArc Capital Management, LLC and Devesh Gandhi collectively hold 2,876,407 shares of KalVista Pharmaceuticals Inc. Class A Common Stock.
• This represents 5.6% of the total outstanding shares.
• The filing is made under Schedule 13G, indicating passive ownership.
• Devesh Gandhi is the Sole Member of SilverArc Capital Management, LLC.
• Various investment funds managed by SilverArc Capital Management, LLC also hold portions of these shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, as a significant passive stake by an investment manager suggests confidence in the company's long-term prospects, though it does not indicate active involvement or immediate catalysts.

Positives

• SilverArc Capital Management, LLC and Devesh Gandhi have taken a significant passive stake (5.6%) in KalVista Pharmaceuticals Inc., which could be interpreted as a vote of confidence in the company's future prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Risks

• The filing does not explicitly mention any risks, as it is a Schedule 13G disclosure of beneficial ownership.
• Potential future changes in SilverArc's investment strategy could lead to a reduction or sale of their stake, impacting KalVista's stock price.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from KalVista Pharmaceuticals Inc. The future outlook for KalVista would depend on its own business operations and disclosures.

Management Comments

• "As of the date of this Report, SilverArc Capital Management, LLC ("SilverArc"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 2,876,407 shares, or 5.62% of the Common Stock believed to be outstanding, as a result of acting as investment adviser to various clients."
• "Gandhi is the Sole Member of SilverArc and as such is deemed to be the beneficial owner of 2,876,407 shares, or 5.62% of the Common Stock believed to be outstanding."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that significant passive stake disclosures by investment managers like SilverArc Capital Management often signal a belief in the target company's underlying value or potential for growth, especially in the biopharmaceutical sector where clinical trial progress and regulatory approvals are key value drivers.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an investment manager may be viewed positively, potentially signaling confidence and attracting further investor interest.
• KalVista Pharmaceuticals Inc.: The filing confirms a substantial institutional investor's passive interest, which can contribute to stock stability and visibility.

Next Steps

• Monitor KalVista Pharmaceuticals Inc. for further disclosures regarding its business operations, clinical trials, and financial performance.
• Observe any future changes in SilverArc Capital Management's stake in KalVista Pharmaceuticals Inc.

Key Dates

Recommendation

This filing is a passive ownership disclosure (Schedule 13G) and does not contain operational or financial results of KalVista Pharmaceuticals Inc. While the 5.6% stake by SilverArc Capital Management suggests some level of confidence, it does not provide sufficient information for a buy or sell recommendation. It warrants a 'hold' to monitor further company developments and potential changes in this stake.

Keywords

KalVista Pharmaceuticals, SilverArc Capital Management, Devesh Gandhi, Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Adviser, SEC Filing